Discover
DSGN
Design Therapeutics, Inc.
13.99
1 x 10.32
1 x 18.39
bid
ask
+
0.22
1.60%
undefined @ 04:00 PM
13.99 +0.00 (0.00%)
| Ytd | 49.15% | |
| 1y | 252.39% |
13.65
day range
14.17
3.97
52 week range
15.79
| Open | 13.97 | Prev Close | 13.77 | Low | 13.65 | High | 14.17 | Mkt Cap | 873.77M |
| Vol | 414.60K | Avg Vol | 964.46K | EPS | -1.18 | P/E | -11.86 | Forward P/E | -5.13 |
| Beta | 1.83 | Short Ratio | 19.61 | Inst. Own | 56.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 12.37 | 200-d Avg | 10.65 | 1yr Est | 7.00 |
| Income Statement | |||
| Operating Expenses | 22.18M | ||
| Research and Development Expense | 16.39M | ||
| Selling, General and Administrative Expense | 5.79M | ||
| Operating Income | -22.18M | ||
| Net Income | -20.16M | ||
| Net Income Common Stock | -20.16M | ||
| Net Income Common Stock (USD) | -20.16M | ||
| Consolidated Income | -20.16M | ||
| Earnings per Basic Share | -0.32 | ||
| Earnings per Basic Share (USD) | -0.32 | ||
| Earnings per Diluted Share | -0.32 | ||
| Earning Before Interest & Taxes (EBIT) | -20.16M | ||
| Earning Before Interest & Taxes (USD) | -20.16M | ||
| Weighted Average Shares | 62.51M | ||
| Weighted Average Shares Diluted | 62.51M | ||
| Balance Sheet | |||
| Cash and Equivalents | 12.91M | ||
| Cash and Equivalents (USD) | 12.91M | ||
| Investments | 194.49M | ||
| Investments Current | 194.49M | ||
| Current Assets | 212.01M | ||
| Property, Plant & Equipment Net | 3.12M | ||
| Total Assets | 215.13M | ||
| Total Debt | 2.03M | ||
| Current Liabilities | 11.24M | ||
| Debt Non-Current | 2.03M | ||
| Total Liabilities | 13.27M | ||
| Accumulated Retained Earnings (Deficit) | -334.81M | ||
| Accumulated Other Comprehensive Income | -771.00K | ||
| Shareholders Equity | 201.86M | ||
| Shareholders Equity (USD) | 201.86M | ||
| Assets Non-Current | 3.12M | ||
| Total Debt (USD) | 2.03M | ||
| Liabilities Non-Current | 2.03M | ||
| Trade and Non-Trade Payables | 3.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 225.00K | ||
| Net Cash Flow from Financing | 605.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 137.00K | ||
| Capital Expenditure | -21.00K | ||
| Issuance (Purchase) of Equity Shares | 605.00K | ||
| Net Cash Flow from Investing | 15.06M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 15.08M | ||
| Net Cash Flow from Operations | -15.52M | ||
| Share Based Compensation | 3.87M | ||